Related Experiment Video
Updated: Jul 7, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis.
Y Suzuki1, T Matsumoto, S Okamoto
1Toho University Sakura Medical Center, Sakura, Japan. yasuo-suzuki@sakura.med.toho-u.ac.jp
Summary
Lecithinized superoxide dismutase (PC-SOD) showed potential in improving ulcerative colitis (UC) symptoms. Further trials are needed to confirm the efficacy of PC-SOD 40 mg/day for UC treatment.
Area of Science:
- Gastroenterology
- Pharmacology
- Biochemistry
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Current treatments for UC have limitations and side effects.
- Novel therapeutic agents are needed for UC management.
Purpose of the Study:
- To evaluate the safety and efficacy of lecithinized superoxide dismutase (PC-SOD) in patients with UC.
- To determine optimal dosage and identify potential side effects of PC-SOD.
Main Methods:
- A pilot study involving patients with UC treated with PC-SOD at daily doses of 40 mg and 80 mg for 4 weeks.
- Efficacy was measured using the UC-Disease Activity Index (DAI).
- Safety was assessed by monitoring and recording all adverse events.
Main Results:
- Significant reduction in UC-DAI total score from baseline in both 40 mg and 80 mg PC-SOD groups.
- PC-SOD 80 mg was not significantly superior to PC-SOD 40 mg.
- PC-SOD was found to be safe at both dosages, with fewer side effects reported in the 80 mg group.
Conclusions:
- PC-SOD demonstrated rapid improvement in UC symptoms compared to existing therapies.
- A 40 mg daily dose of PC-SOD shows promise for UC treatment.
- A double-blind, placebo-controlled trial is recommended to validate these findings.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...